Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | GLS2 | Q9UI32 | 1/20 | 0.34 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7739836 | 0.84 | ACHE (0.42) | ACHEBACE1ALOX5PTGS2PTPN1 | |
| SCHEMBL1998499 | 0.82 | ACHE (0.44) | ACHEBACE1ALOX5PTGS2PTPN1 | |
| SCHEMBL9131916 | 0.78 | ACHE (0.35) | ACHEBACE1ALOX5PTGS2PTPN1 | |
| SCHEMBL357488 | 0.78 | ACHE (0.43) | ACHEBACE1ALOX5PTGS2PTPN1 | |
| SCHEMBL27482175 | 0.77 | ACHE (0.46) | ACHEBACE1ALOX5PTGS2PTPN1 | |
| SCHEMBL6903485 | 0.77 | ACHE (0.46) | ACHEBACE1ALOX5PTGS2PTPN1 | |
| SCHEMBL11543697 | 0.77 | ACHE (0.46) | ACHEBACE1ALOX5PTGS2PTPN1 | |
| SCHEMBL6898154 | 0.77 | ACHE (0.46) | ACHEBACE1ALOX5PTGS2PTPN1 | |
| SCHEMBL6896832 | 0.77 | ACHE (0.46) | ACHEBACE1ALOX5PTGS2PTPN1 | |
| SCHEMBL243893 | 0.77 | ACHE (0.46) | ACHEBACE1ALOX5PTGS2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653307-B2 | Liphagal enantiomers and their derivatives and precursors, and enantioselective methods of making the same | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-02-18 | — | — | US | disclosed |
| US-20130023676-A1 | LIPHAGAL ENANTIOMERS AND THEIR DERIVATIVES AND PRECURSORS, AND ENANTIOSELECTIVE METHODS OF MAKING THE SAME | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2013-01-24 | — | — | US | disclosed |
| WO-2012166987-A2 | LIPHAGAL ENANTIOMERS AND THEIR DERIVATIVES AND PRECURSORS, AND ENANTIOSELECTIVE METHODS OF MAKING THE SAME | CALIFORNIA INSTITUTE TECHNOLOGY (US) | 2012-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023676-A1 | LIPHAGAL ENANTIOMERS AND THEIR DERIVATIVES AND PRECURSORS, AND ENANTIOSELECTIVE METHODS OF MAKING THE SAME | LIPC, LIPE, LIPA | ACHE 1424/4885BACE1 1305/4885ALOX5 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.